NCT01756183

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Unresectable Gastric Cancer

Exploratory Study on the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients With Unresectable Gastric Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Exploratory the S-1 + Paclitaxel Chemotherapy for Creating the Operation Chance in the Patients with Unresectable Gastric Cancer

Detailed description

To assess the effectiveness and safety of S-1 + Paclitaxel for the peri-operative chemotherapy in Chinese patients with unresectable gastric cancer, so as to further find out the optimal protocol for the peri-operative chemotherapy in the patients with gastric cancer.

Conditions

• Surgically-Created Resection Cavity
• Drug Safety

Interventions

Type	Name	Description
DRUG	S-1 + Paclitaxel Chemotherapy	Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week. Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1

Timeline

• Start date: 2011-09-01
• Primary completion: 2013-09-01
• Completion: 2016-12-01
• First posted: 2012-12-25
• Last updated: 2012-12-25

Locations

1 site across 1 country: China